Fund profile by ISIN IE00BF0H7608
L&G Pharma Breakthrough UCITS ETF
Research L&G Pharma Breakthrough UCITS ETF by ISIN IE00BF0H7608: TER 0.49%, domicile Ireland, accumulating, and 1-year price performance +17.4%.
ISINIE00BF0H7608
TER0.49%
DomicileIreland
Distribution policyAccumulating
IndexSolactive Pharma Breakthrough Value
Fund size22M
Holdings36
1-year price performance+17.4%
Exchange listings and tradability
| Ticker | Exchange | Currency | Country | Avg daily turnover | Avg daily shares |
|---|---|---|---|---|---|
| ETLI.DE | XETRADefault at German brokers | EUR | Ireland | €67K | 5,119 |
| BIOT.MI | ETFP | EUR | Ireland | €14K | 1,071 |
| BIOT.AS | XAMS | EUR | Ireland | €10K | 755 |
| BIOT.SW | SW | CHF | Ireland | €7K | 563 |
| BIGT.L | LSE | GBX | Ireland | €5K | 397 |
| BIOT.L | LSE | USD | Ireland | €3K | 227 |
Avg daily turnover is the 90-day average, converted to euros so venues in different currencies can be compared; avg daily shares is the same window in units. The most traded listing is shown first. This fund trades on a German exchange. As of 2026-10-12.
Largest holdings
The 10 largest holdings make up 36.87% of the fund, which holds 36 positions in total. As of 2026-09-13.
| Holding | Symbol | Weight |
|---|---|---|
| Travere Therapeutics Inc Ordinary Shares | TVTX | 5.59% |
| Xencor Inc | XNCR | 5.54% |
| Halozyme Therapeutics Inc | HALO | 3.63% |
| Xeris Biopharma Holdings Inc | XERS | 3.34% |
| argenx SE ADR | ARGX | 3.30% |
| Ligand Pharmaceuticals Inc | LGND | 3.23% |
| Jazz Pharmaceuticals PLC | JAZZ | 3.17% |
| Royalty Pharma PLC Class A | RPRX | 3.11% |
| Zevra Therapeutics Inc | ZVRA | 3.00% |
| Incyte Corp | INCY | 2.95% |
Performance is the historical price return of the representative listing. Distributions are excluded and past performance is not a forecast.